ストックスクリーナーアプリを入手
25.88
0.54%
0.14
前日終値:
$25.74
開ける：
$25.9
24時間の取引高:
32.12M
Relative Volume:
0.81
時価総額：
$147.14B
収益：
$63.83B
当期純損益:
$10.77B
株価収益率:
13.77
EPS:
1.88
ネットキャッシュフロー:
$12.44B
1週間 パフォーマンス:
+2.94%
1か月 パフォーマンス:
+2.94%
6か月 パフォーマンス:
-1.60%
1年 パフォーマンス:
-10.08%
1日の値動き範囲:
$25.76
$26.11
1週間の範囲:
$25.01
$26.11
52週間の値動き範囲:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.88 | 142.54B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
How Much Would It Take To Earn $100 A Month From Pfizer Stock - Yahoo Finance
Pfizer Rises 0.24% Amid Legal and Clinical Setbacks, Trading Volume Ranks 92nd - AInvest
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire Inc.
Enanta files patent suit against Pfizer in Europe - Endpoints News
Pfizer battles another Paxlovid lawsuit from Enanta - Yahoo Finance
Myositis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare, Genentech - Barchart.com
Pfizer’s Latest Study on NSCLC Treatment: A Potential Game-Changer? - TipRanks
Pfizer sued by Enanta in EU patent fight (ENTA:NASDAQ) - Seeking Alpha
Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement - TipRanks
Enanta files patent infringement suit against Pfizer over Paxlovid - Investing.com
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union - FinancialContent
Stock Analysis | Pfizer OutlookMixed Signals Amid Volatile Market Dynamics - AInvest
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Pfizer’s (PFE) Oncology Gamble is Finally Paying Off - TipRanks
Pfizer says Canada just approved its new COVID-19 vaccine for this fall - Global News
Pfizer, Astellas Beat Challenge To Prostate Cancer Drug Patent - Law360
Pfizer Oncology Drugs Drive Sales In Q2: Will The Trend Continue? - Barchart.com
Pfizer Inc. Stock (PFE) Opinions on Recent Clinical Trial Results - Quiver Quantitative
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue? - Yahoo Finance
Pfizer Canada and HPIC Mark 30 Years of Humanitarian Partnership Delivering Global Health Impact - Seeking Alpha
Analyst recommendations: Arista Networks, Caterpillar, Pfizer, Broadcom, Nvidia… - MarketScreener
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True? - Yahoo Finance
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine - BioSpace
Lobbying Update: $3,710,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer/BioNTech updated COVID vaccine authorized in Canada - Seeking Alpha
Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag - insights.citeline.com
Hung Trinh: Pfizer Completes Licensing Agreement with 3SBio - Oncodaily
Pfizer price surrounded with positive pressuresForecast today18-08-2025 - Economies.com
Pfizer’s sickle cell disease candidate fails Phase III trial - Yahoo Finance
Pfizer sickle cell hopes dim as inclacumab fails in late-stage trial - The Pharma Letter
Pfizer suffers another hit to its GBT sickle cell portfolio - pharmaphorum
Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment - Yahoo Finance
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer's Value Re-rating: Can Strong Institutional Interest and a Revitalized R&D Pipeline Justify a Buy? - AInvest
Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating - MSN
Pfizer Inc. - Britannica
Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given... - Medical Dialogues
Pfizer's Sickle Cell Drug Fails to Meet Main Goal, Safety Profile Remains a Potential Asset - AInvest
Can Pfizer Inc. maintain its current growth rateJuly 2025 Macro Moves & Intraday High Probability Setup Alerts - thegnnews.com
Is Pfizer's Turnaround Real, and Is the 6.5% Dividend Safe? - AInvest
Pfizer: This Is What Bulls Waited For - Seeking Alpha
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - MSN
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis Treatment - MSN
Pfizer and AbbVie Advance Pediatric Antibiotic Study: Market Implications - MSN
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings - MSN
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer? - MSN
Pfizer’s Tukysa Study: A Closer Look at Its Korean Market Impact - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer’s Talzenna®: New Korea PMS Study Update and Market Insights - TipRanks
Pfizer’s Promising Migraine Study: A New Hope for Adolescents - TipRanks
A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions - insights.citeline.com
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
1.18%
1.46%
大文字化:
|
ボリューム (24 時間):